Your browser doesn't support javascript.
loading
Droperidol administration among emergency department patients with abdominal pain, nausea, and vomiting.
Ernst, Ryan; Wagstaff, Holden; Smith, Mckayla; O'Brien, Liam; Mainor, Hannah; Madsen, Troy.
Afiliación
  • Ernst R; University of Utah Department of Emergency Medicine, 30 N Mario Capecchi, HELIX Bldg, Salt Lake City, UT 84112, United States of America. Electronic address: ryan.ernst@utah.edu.
  • Wagstaff H; University of Utah Department of Emergency Medicine, 30 N Mario Capecchi, HELIX Bldg, Salt Lake City, UT 84112, United States of America. Electronic address: holden.wagstaff@hsc.utah.edu.
  • Smith M; University of Utah Department of Emergency Medicine, 30 N Mario Capecchi, HELIX Bldg, Salt Lake City, UT 84112, United States of America.
  • O'Brien L; University of Utah Department of Emergency Medicine, 30 N Mario Capecchi, HELIX Bldg, Salt Lake City, UT 84112, United States of America.
  • Mainor H; University of Utah Department of Emergency Medicine, 30 N Mario Capecchi, HELIX Bldg, Salt Lake City, UT 84112, United States of America.
  • Madsen T; University of Utah Department of Emergency Medicine, 30 N Mario Capecchi, HELIX Bldg, Salt Lake City, UT 84112, United States of America; Intermountain Health Park City Hospital Department of Emergency Medicine, 900 Round Valley Drive, Park City, UT 84060, United States of America.
Am J Emerg Med ; 85: 44-47, 2024 Aug 05.
Article en En | MEDLINE | ID: mdl-39217779
ABSTRACT
STUDY

OBJECTIVE:

The primary objective of this study was to examine the common usage patterns of droperidol in the relatively unrestricted environment of an urban, academic medical center. We focused specifically on the most common use of droperidol in our department patients with a chief complaint of abdominal pain, nausea, and/or vomiting.

METHODS:

For this retrospective, observational, single-center study, we extracted records of all administrations of droperidol from August 2019 to August 2020. Patients with a chief complaint of abdominal pain, nausea, or vomiting, or any combination thereof, were included in data analysis.

RESULTS:

Between April 2019 to August 2020, 830 discrete patient visits involving droperidol administration were identified, comprising 706 patients. The average age was 39 years old with a range of 15 to 80. Seven patients (0.08%) were younger than 18, and 35 (4%) were older than 65. Five hundred sixty-five patients (68%) were female. Droperidol doses ranged from 0.625 mg to 5 mg intravenous (IV), with a median dose of 0.625 mg (interquartile range 0.625-1.25 mg), with 590 patients (71%) receiving a dose of 0.625 mg. Only 19 patients (2.3%) had a documented adverse event. Seven had akathisia or restlessness, 7 had anxiety or agitation, 3 had dystonia or stiffness, 1 had fatigue, and 1 had dizziness. For the entire cohort, there were no cardiac dysrhythmias, syncope, seizures, other major adverse events, or fatalities recorded.

CONCLUSION:

At one institution, droperidol is being used commonly for the chief complaints of abdominal pain, nausea, and/or vomiting. The preferred dosing is nearly universally below the 2.5 mg IV dose for which the FDA warning applies. Similar to previous studies, identification of adverse events was rare, and no major adverse outcomes such as dysrhythmia or death were identified.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Am J Emerg Med Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Am J Emerg Med Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos